Payment overview · 2025
General Payments
$316.02
16 reported records · 9 companies
Healthcare provider profile · identity verified
Thomas D Ogara, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RENO, NV · NPI 1841287026
Verified facts
What the public records show
CMS Open Payments records show Thomas D Ogara, MD received $316.02 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $112.44 | 35.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.73 | 14.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.62 | 11.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.14 | 11.1% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.18 | 6.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.40 | 6.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.89 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.75 | 5.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.87 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.02 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $112.44 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 117 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
150 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 830 | 205 |
| Gabapentin | Gabapentin | 658 | 140 |
| Metformin Hcl | Metformin Hcl | 619 | 165 |
| Losartan Potassium | Losartan Potassium | 583 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 515 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 480 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 136 |
| Lisinopril | Lisinopril | 415 | 124 |
| Alprazolam | Alprazolam | 382 | 66 |
| Omeprazole | Omeprazole | 364 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 84 |
| Zolpidem Tartrate | Zolpidem Tartrate | 296 | 49 |
| Trazodone Hcl | Trazodone Hcl | 284 | 71 |
| Carvedilol | Carvedilol | 272 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 76 |
| Allopurinol | Allopurinol | 229 | 60 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 223 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 73 |
| Prednisone | Prednisone | 218 | 162 |
| Glipizide | Glipizide | 189 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 43 |
| Simvastatin | Simvastatin | 174 | 43 |
| Furosemide | Furosemide | 173 | 57 |
| Potassium Chloride | Potassium Chloride | 173 | 57 |
| Lansoprazole | Lansoprazole | 168 | 45 |
| Enalapril Maleate | Enalapril Maleate | 164 | 50 |
| Meloxicam | Meloxicam | 160 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 41 |
| Atenolol | Atenolol | 158 | 44 |
| Ozempic | Semaglutide | 150 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 36 |
| Lovastatin | Lovastatin | 134 | 36 |
| Tramadol Hcl | Tramadol Hcl | 134 | 19 |
| Celecoxib | Celecoxib | 130 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 128 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 21 |
| Baclofen | Baclofen | 124 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 38 |
| Sertraline Hcl | Sertraline Hcl | 121 | 29 |
| Lorazepam | Lorazepam | 119 | 14 |
| Eliquis | Apixaban | 117 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 115 | 29 |
| Colestipol Hcl | Colestipol Hcl | 110 | 35 |
| Ibuprofen | Ibuprofen | 109 | 26 |
| Methylprednisolone | Methylprednisolone | 104 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 101 | 87 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 20 |
| Cefdinir | Cefdinir | 93 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 18 |
| Acyclovir | Acyclovir | 82 | 37 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 26 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Glimepiride | Glimepiride | 79 | 26 |
| Spironolactone | Spironolactone | 79 | 27 |
| Diazepam | Diazepam | 78 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | 18 |
| Ezetimibe | Ezetimibe | 77 | 24 |
| Clonazepam | Clonazepam | 76 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 20 |
| Mirtazapine | Mirtazapine | 73 | 19 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Synthroid | Levothyroxine Sodium | 71 | 15 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Terazosin Hcl | Terazosin Hcl | 69 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 17 |
| Azithromycin | Azithromycin | 65 | 52 |
| Sucralfate | Sucralfate | 65 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 19 |
| Metformin Hcl Er | Metformin Hcl | 61 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | suppressed |
| Naproxen | Naproxen | 55 | 15 |
| Temazepam | Temazepam | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 17 |
| Benazepril Hcl | Benazepril Hcl | 53 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Finasteride | Finasteride | 51 | 19 |
| Xarelto | Rivaroxaban | 51 | 11 |
| Amoxicillin | Amoxicillin | 49 | 43 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 43 | 12 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 16 |
| Verapamil Er | Verapamil Hcl | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | 14 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Famotidine | Famotidine | 34 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Testosterone | Testosterone | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Estradiol | Estradiol | 30 | 12 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 11 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 12 |
| Propranolol Hcl | Propranolol Hcl | 26 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Valsartan | Valsartan | 25 | 11 |
| Armour Thyroid | Thyroid,pork | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 20 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.02 · 16 records | GlaxoSmithKline, LLC. | Dexcom G6 Transmitter, ELIQUIS, KYPHON EXPRESS II KYPHOPAK TRAY, NURTEC ODT, NUZYRA, OTEZLA, PAXLOVID, REPATHA, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error